Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This is a randomized (4:1) Phase 1 b safety trial in adults who have completed their full
COVID-19 vaccination schedule at least 30 days prior to study entry.